Who are Polatuzumab Vedotin, Rituximab, Lenalidomide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): LONCASTUXIMAB TESIRINE, Uplizna, Blincyto, BLINATUMOMAB, MONJUVI, IL-2 pre-treated CD19 cells.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/polatuzumab-vedotin-rituximab-lenalidomide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Polatuzumab Vedotin, Rituximab, Lenalidomide — Competitive Intelligence Brief

Polatuzumab Vedotin, Rituximab, Lenalidomide (Polatuzumab Vedotin, Rituximab, Lenalidomide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody-drug conjugate. Area: Oncology.

phase 2 Monoclonal antibody-drug conjugate CD19 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Polatuzumab Vedotin, Rituximab, Lenalidomide (Polatuzumab Vedotin, Rituximab, Lenalidomide) — Yan Zhang, MD. Monoclonal antibody targeting CD19, conjugated with microtubule inhibitor

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Polatuzumab Vedotin, Rituximab, Lenalidomide TARGET	Polatuzumab Vedotin, Rituximab, Lenalidomide	Yan Zhang, MD	phase 2	Monoclonal antibody-drug conjugate	CD19
LONCASTUXIMAB TESIRINE	LONCASTUXIMAB TESIRINE		marketed	Antibody-Drug Conjugate (ADC)	CD19	2021-01-01
Uplizna	INEBILIZUMAB	Viela Bio	marketed	CD19-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD19	2020-01-01
Blincyto	blinatumomab	Amgen	marketed	Bispecific CD19-directed CD3-directed T Cell Engager	B-lymphocyte antigen CD19	2014-01-01
BLINATUMOMAB	BLINATUMOMAB		marketed		CD19, CD3	2014-01-01
MONJUVI	TAFASITAMAB-CXIX	MORPHOSYS US INC	marketed		B-lymphocyte antigen CD19
IL-2 pre-treated CD19 cells	IL-2 pre-treated CD19 cells	jiangjingting	marketed	Adoptive cell therapy	CD19

Recent regulatory actions (last 90 days)

2026-02-20 — LONCASTUXIMAB TESIRINE · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody-drug conjugate class)

GlaxoSmithKline · 2 drugs in this class
RemeGen Co., Ltd. · 2 drugs in this class
Copharos · 1 drug in this class
Eastern Cooperative Oncology Group · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Mirati Therapeutics Inc. · 1 drug in this class
NYU Langone Health · 1 drug in this class
The Lymphoma Academic Research Organisation · 1 drug in this class
Astellas Pharma Global Development, Inc. · 1 drug in this class
Yan Zhang, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Polatuzumab Vedotin, Rituximab, Lenalidomide — Competitive Intelligence Brief. https://druglandscape.com/ci/polatuzumab-vedotin-rituximab-lenalidomide. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab